Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants

OBJECTIVES: The objective of this pharmacometric (PMX) study was to (i) characterize population pharmacokinetics (PPK) and exposure-pain response associations following intranasal (0.1 mg/kg) or intravenous (IV, 0.05 mg/kg) administration of nalbuphine, with the goal to (ii) evaluate strategies for...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfiffner, Miriam, Berger-Olah, Eva, Vonbach, Priska, Pfister, Marc, Gotta, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926166/
https://www.ncbi.nlm.nih.gov/pubmed/35311056
http://dx.doi.org/10.3389/fped.2022.837492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926166/
https://www.ncbi.nlm.nih.gov/pubmed/35311056
http://dx.doi.org/10.3389/fped.2022.837492

Ejemplares similares